Pazopanib G.L. Pharma
On the Bulgarian pack: Пазопаниб G.L. Pharma 200 mg филмирани таблетки
200 mg film-coated tablets multipack · film-coated tablets
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Pazopanib
- Made by
- G.L. Pharma GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet read the official leaflet for this product. The exact uses and dose are in the leaflet inside the pack. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (pazopanib). It describes the substance, not this Bulgarian product — its uses and doses can differ.
In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors.
In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human tumor xenografts in mice.
In vitro studies demonstrated that pazopanib is metabolized by CYP3A4 with a minor contribution from CYP1A2 and CYP2C8.
Effect of Food Systemic exposure to pazopanib is increased when administered with food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-19
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (pazopanib). It describes the substance, not this Bulgarian product — its uses and doses can differ.
WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials.
The most common adverse reactions in patients with STS (≥ 20%) are fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, vomiting, tumor pain, hair color changes, musculoskeletal pain, headache, dysgeusia, dyspnea, and skin hypopigmentation.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States8 matching products
European UnionNo exact match for this strength and form
Spain5 matching products
Details
| Made by | G.L. Pharma GmbH · Austria |
|---|---|
| Active substance | Pazopanib |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 200 mg film-coated tablets multipack |
| Form | film-coated tablets |
| Pack sizes | 60 · 90 |
| Classification | L01XE03 · Cancer treatments and immune-system medicines |
| Name in the register | Пазопаниб G.L. Pharma 200 mg филмирани таблетки |
| Reg. no. | 20220090 |
Source: Bulgarian Drug Agency register · 2026-08-01 · not reviewed by a clinician
Източник: Изпълнителна агенция по лекарствата (ИАЛ). The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- film-coated tablets4 products
- 200 mg film-coated tablets multipack
- 200 mg
- 400 mg
- 400 mg film-coated tablets multipack
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.